Payment overview · 2025
General Payments
$532.44
7 reported records · 2 companies
Healthcare provider profile · identity verified
Boris Veysman
Allopathic & Osteopathic Physicians|Emergency Medicine · FREEHOLD, NJ · NPI 1891846234
Verified facts
What the public records show
CMS Open Payments records show Boris Veysman received $532.44 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 79.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $422.24 | 79.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.20 | 20.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $532.44 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $217.55 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $204.69 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
121 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
187 | 52 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 846 | 118 |
| Prednisone | Prednisone | 317 | 165 |
| Vascepa | Icosapent Ethyl | 259 | 71 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 255 | 71 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 224 | 56 |
| Meloxicam | Meloxicam, Submicronized | 203 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 38 |
| Linzess | Linaclotide | 187 | 52 |
| Single Use Swab | Alcohol Antiseptic Pads | 164 | 56 |
| Gabapentin | Gabapentin | 163 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 144 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 137 | 52 |
| Mounjaro | Tirzepatide | 132 | 29 |
| Alprazolam | Alprazolam | 126 | 40 |
| Clobetasol Propionate | Clobetasol Propionate | 126 | 30 |
| Creon | Lipase/Protease/Amylase | 121 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 120 | 84 |
| Azithromycin | Azithromycin | 117 | 93 |
| Losartan Potassium | Losartan Potassium | 117 | 44 |
| Metformin Hcl | Metformin Hcl | 109 | 40 |
| Ozempic | Semaglutide | 107 | 33 |
| Icosapent Ethyl | Icosapent Ethyl | 106 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 34 |
| Restasis | Cyclosporine | 105 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 28 |
| Furosemide | Furosemide | 98 | 40 |
| Metformin Er Gastric | Metformin Hcl | 93 | 36 |
| Ondansetron Odt | Ondansetron | 91 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 29 |
| Omeprazole | Omeprazole | 88 | 35 |
| Eliquis | Apixaban | 87 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 87 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 43 |
| Lidocaine | Lidocaine | 80 | 22 |
| Liothyronine Sodium | Liothyronine Sodium | 78 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 35 |
| Zileuton Er | Zileuton | 74 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 24 |
| Jardiance | Empagliflozin | 72 | 19 |
| Ammonium Lactate | Ammonium Lactate | 71 | 17 |
| Cyclosporine | Cyclosporine | 71 | 27 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 70 | 51 |
| Lisinopril | Lisinopril | 70 | 22 |
| Doxepin Hcl | Doxepin Hcl | 68 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 63 | 12 |
| Levofloxacin | Levofloxacin | 63 | 36 |
| Cefuroxime | Cefuroxime Axetil | 59 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 16 |
| Sertraline Hcl | Sertraline Hcl | 56 | 20 |
| Fluconazole | Fluconazole | 53 | 28 |
| Aripiprazole Odt | Aripiprazole | 52 | suppressed |
| Ibuprofen | Ibuprofen | 51 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 19 |
| Meloxicam | Meloxicam | 50 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 28 |
| Celecoxib | Celecoxib | 49 | 18 |
| Clonazepam | Clonazepam | 49 | 17 |
| Hydromorphone Hcl | Hydromorphone Hcl | 49 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 17 |
| Tacrolimus | Tacrolimus | 47 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 11 |
| Allopurinol | Allopurinol | 45 | 16 |
| Atenolol | Atenolol | 45 | 22 |
| Clindamycin Hcl | Clindamycin Hcl | 45 | 34 |
| Montelukast Sodium | Montelukast Sodium | 45 | 18 |
| Potassium Chloride | Potassium Chloride | 45 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | 15 |
| Januvia | Sitagliptin Phosphate | 42 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 41 | 38 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 41 | 24 |
| Mupirocin | Mupirocin | 40 | 23 |
| Cefdinir | Cefdinir | 39 | 32 |
| Famotidine | Famotidine | 38 | 14 |
| Farxiga | Dapagliflozin Propanediol | 38 | 13 |
| Estradiol | Estradiol | 37 | 13 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Metronidazole | Metronidazole | 37 | 19 |
| Megestrol Acetate | Megestrol Acetate | 36 | 18 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Calcipotriene | Calcipotriene | 35 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 13 |
| Latanoprost | Latanoprost | 33 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 33 | 23 |
| Simvastatin | Simvastatin | 33 | 12 |
| Valsartan | Valsartan | 33 | 12 |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 32 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 31 | suppressed |
| Procto-Med Hc | Hydrocortisone | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | 11 |
| Sucralfate | Sucralfate | 29 | 23 |
| Carvedilol | Carvedilol | 28 | 12 |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Flunisolide | Flunisolide | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | 17 |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | 11 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | 13 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 19 | 11 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Zafirlukast | Zafirlukast | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | 11 |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Otezla | Apremilast | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 11 |
| Zaleplon | Zaleplon | 14 | suppressed |
| Desonide | Desonide | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | 11 |
| Valacyclovir | Valacyclovir Hcl | 13 | 13 |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Nizatidine | Nizatidine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $532.44 · 7 records | ABBVIE INC. | Ozempic, QULIPTA, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error